Disease Information

General Information of the Disease (ID: DIS00145)

• Name: Hodgkin lymphoma
• ICD: ICD-11: 2B30

Type(s) of Resistant Mechanism of This Disease

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Brentuximab vedotin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Pleiotropic ABC efflux transporter of multiple drugs CDR /Multidrug resistance protein 1 (CDR1/ABCB1) [1]

• Resistant Disease: Hodgkin lymphoma [ICD-11: 2B30.0]
• Molecule Alteration: Expression; Up-regulation
• Resistant Drug: Brentuximab vedotin
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Inhibition; hsa04210
• Cell Pathway Regulation: Cell proliferation; Activation; hsa05200
• In Vitro Model: L428 cells; Lymph; Homo sapiens (Human); CVCL_1361
• In Vitro Model: KM-H2 cells; Lymph; Homo sapiens (Human); CVCL_1330
• In Vivo Model: Female NSG mouse model; Mus musculus
• Experiment for Molecule Alteration: Flow cytometry
• Experiment for Drug Resistance: MTS assay
• Mechanism Description: Competitive inhibition of MDR1 restored sensitivity to BV in our BV-resistant cell lines by increasing intracellular MMAE levels, and potentiated BV activity in BV-resistant HL tumors in a human xenograft mouse model.

References

• Ref 1: Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin LymphomaClin Cancer Res. 2020 Mar 1;26(5):1034-1044. doi: 10.1158/1078-0432.CCR-19-1768. Epub 2019 Dec 6.